II.1.8 Alkyl Nitrites by Yasuo Seto
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Novel Antagonists for the Human Adenosine
UvA-DARE (Digital Academic Repository) Novel antagonists for the human adenosine A2A and A3 receptor via purine nitration: synthesis and biological evaluation of C2-substituted 6- trifluoromethylpurines and 1-deazapurines Koch, M. Publication date 2011 Document Version Final published version Link to publication Citation for published version (APA): Koch, M. (2011). Novel antagonists for the human adenosine A2A and A3 receptor via purine nitration: synthesis and biological evaluation of C2-substituted 6-trifluoromethylpurines and 1- deazapurines. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:05 Oct 2021 Novel antagonists for the human adenosine A Novel antagonists for the human adenosine Uitnodiging Novel antagonists for the voor het bijwonen van human adenosine de openbare verdediging van het proefschrift van A2A and A3 receptor via purine nitration Melle Koch op vrijdag 21 oktober 2011 om 14:00 uur in de Agnietenkapel van de Universiteit van Amsterdam Synthesis and biological evaluation Oudezijds Voorburgwal 231 of C2-substituted te Amsterdam 2A Na afloop van de promotie and A 6-trifluoromethylpurines zal hier tevens de receptie . -
Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
Review Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics Joel Mintz 1,†, Anastasia Vedenko 2,†, Omar Rosete 3 , Khushi Shah 4, Gabriella Goldstein 5 , Joshua M. Hare 2,6,7 , Ranjith Ramasamy 3,6,* and Himanshu Arora 2,3,6,* 1 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA; [email protected] 2 John P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] (A.V.); [email protected] (J.M.H.) 3 Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] 4 College of Arts and Sciences, University of Miami, Miami, FL 33146, USA; [email protected] 5 College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA; [email protected] 6 The Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 7 Department of Medicine, Cardiology Division, Miller School of Medicine, University of Miami, Miami, FL 33136, USA * Correspondence: [email protected] (R.R.); [email protected] (H.A.) † These authors contributed equally to this work. Abstract: Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumori- Citation: Mintz, J.; Vedenko, A.; genic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the Rosete, O.; Shah, K.; Goldstein, G.; level of production, the oxidative/reductive (redox) environment in which this radical is generated, Hare, J.M; Ramasamy, R.; Arora, H. -
Mechanisms of Nitric Oxide Reactions Mediated by Biologically Relevant Metal Centers
Struct Bond (2014) 154: 99–136 DOI: 10.1007/430_2013_117 # Springer-Verlag Berlin Heidelberg 2013 Published online: 5 October 2013 Mechanisms of Nitric Oxide Reactions Mediated by Biologically Relevant Metal Centers Peter C. Ford, Jose Clayston Melo Pereira, and Katrina M. Miranda Abstract Here, we present an overview of mechanisms relevant to the formation and several key reactions of nitric oxide (nitrogen monoxide) complexes with biologically relevant metal centers. The focus will be largely on iron and copper complexes. We will discuss the applications of both thermal and photochemical methodologies for investigating such reactions quantitatively. Keywords Copper Á Heme models Á Hemes Á Iron Á Metalloproteins Á Nitric oxide Contents 1 Introduction .................................................................................. 101 2 Metal-Nitrosyl Bonding ..................................................................... 101 3 How Does the Coordinated Nitrosyl Affect the Metal Center? .. .. .. .. .. .. .. .. .. .. .. 104 4 The Formation and Decay of Metal Nitrosyls ............................................. 107 4.1 Some General Considerations ........................................................ 107 4.2 Rates of NO Reactions with Hemes and Heme Models ............................. 110 4.3 Mechanistic Studies of NO “On” and “Off” Reactions with Hemes and Heme Models ................................................................................. 115 4.4 Non-Heme Iron Complexes .......................................................... -
Nitrosamines EMEA-H-A5(3)-1490
25 June 2020 EMA/369136/2020 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation EC (No) 726/2004 Nitrosamine impurities in human medicinal products Procedure number: EMEA/H/A-5(3)/1490 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ...................................................................................... 2 1. Information on the procedure ............................................................... 7 2. Scientific discussion .............................................................................. 7 2.1. Introduction......................................................................................................... 7 2.2. Quality and safety aspects ..................................................................................... 7 2.2.1. Root causes for presence of N-nitrosamines in medicinal products and measures to mitigate them............................................................................................................. 8 2.2.2. Presence and formation of N-nitrosamines -
A Nitric Oxide/Cysteine Interaction Mediates the Activation of Soluble Guanylate Cyclase
A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase Nathaniel B. Fernhoffa,1, Emily R. Derbyshirea,1,2, and Michael A. Marlettaa,b,c,3 Departments of aMolecular and Cell Biology and bChemistry, University of California, Berkeley, CA 94720; and cCalifornia Institute for Quantitative Biosciences and Division of Physical Biosciences, Lawrence Berkeley National Laboratory, Berkeley, CA 94720 Contributed by Michael A. Marletta, October 1, 2009 (sent for review August 22, 2009) Nitric oxide (NO) regulates a number of essential physiological pro- high activity of the xsNO state rapidly reverts to the low activity of cesses by activating soluble guanylate cyclase (sGC) to produce the the 1-NO state. Thus, all three sGC states (basal, 1-NO, and xsNO) second messenger cGMP. The mechanism of NO sensing was previ- can be prepared and studied in vitro (7, 8). Importantly, these ously thought to result exclusively from NO binding to the sGC heme; results define two different states of purified sGC with heme bound however, recent studies indicate that heme-bound NO only partially NO (7, 8), one with a high activity and one with a low activity. activates sGC and additional NO is involved in the mechanism of Further evidence for a non-heme NO binding site was obtained maximal NO activation. Furthermore, thiol oxidation of sGC cysteines by blocking the heme site with the tight-binding ligand butyl results in the loss of enzyme activity. Herein the role of cysteines in isocyanide, and then showing that NO still activated the enzyme NO-stimulated sGC activity investigated. We find that the thiol mod- (14). -
1,3-Oxazolidin-2-One Derivatives Useeful As Cetp Inhibitors
(19) TZZ Z Z_T (11) EP 2 029 560 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 263/22 (2006.01) C07D 413/04 (2006.01) 24.04.2013 Bulletin 2013/17 C07D 413/10 (2006.01) C07D 417/10 (2006.01) C07D 417/14 (2006.01) A61K 31/421 (2006.01) (2006.01) (2006.01) (21) Application number: 06849136.4 A61K 31/422 A61K 31/427 A61K 31/443 (2006.01) A61P 9/00 (2006.01) (22) Date of filing: 29.12.2006 (86) International application number: PCT/US2006/049494 (87) International publication number: WO 2007/079186 (12.07.2007 Gazette 2007/28) (54) 1,3-OXAZOLIDIN-2-ONE DERIVATIVES USEEFUL AS CETP INHIBITORS 1,3-OXAZOLIDIN-2-ON-DERIVATIVE, DIE ZUR VERWENDUNG ALS CETP-INHIBITOREN GEEIGNET SIND DERIVES DE 1,3-OXAZOLIDIN-2-ONE EN TANT QU’INHIBITEURS DE CETP (84) Designated Contracting States: • SINCLAIR, Peter, J. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Rahway, New Jersey 07065-0907 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • CHEN, Yi-Heng SK TR Rahway, New Jersey 07065-0907 (US) • SMITH, Cameron, J. (30) Priority: 30.12.2005 US 755284 P Rahway, New Jersey 07065-0907 (US) • LI, Hong (43) Date of publication of application: Rahway, New Jersey 07065-0907 (US) 04.03.2009 Bulletin 2009/10 (74) Representative: Hussain, Deeba (73) Proprietor: Merck Sharp & Dohme Corp. Merck & Co., Inc. Rahway, NJ 07065-0907 (US) Patent Department Hertford Road (72) Inventors: Hoddesdon • ALI, Amjad Hertfordshire EN11 9BU (GB) Rahway, New Jersey 07065-0907 (US) • LU, Zhijian (56) References cited: Rahway, New Jersey 07065-0907 (US) EP-A1- 0 294 995 EP-A1- 0 605 729 WO-A-2006/014413 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. -
Accelerating Effect of Ascorbic Acid on A/-Nitrosamine Formation and Nitrosation by Oxyhyponitrite1
[CANCER RESEARCH 39, 3871-3874, October 1979] 0008-5472/79/0039-OOOOS02.00 Accelerating Effect of Ascorbic Acid on A/-Nitrosamine Formation and Nitrosation by Oxyhyponitrite1 Shaw-Kong Chang,2 George W. Harrington,5 Marc Rothstein,3 William A. Shergalis,4 Daniel Swern, and Saroj K. Vohra. Department of Chemistry, Temple University. Philadelphia. Pennsylvania 19122, and the Fels Research Institute. Temple University, Philadelphia. Pennsylvania 19140 ABSTRACT ments to be made readily during the initial and intermediate stages of reaction. DPP as used in this study avoids this The reaction of nitrite ion with ascorbic acid and its effect on difficulty and allows reactions to be studied in situ, yielding the rate of nitrosation of secondary amines have been investi interesting results. The use of DPP as an analytical method for gated by differential pulse polarography in aqueous acidic A/-nitrosamines and as a technique to study some of the chem solution. Ascorbic acid shows nonuniform behavior: it accel istry of W-nitrosamines has been previously reported by us (6- erates the nitrosation of N-methylaniline between pH 1.00 and 8, 31, 32). 1.95, allows the nitrosation of diphenylamine and iminodiace- tonitrile, but inhibits the nitrosation of secondary amines, such MATERIALS AND METHODS as dimethylamine, diethylamine, proline, hydroxyproline, N- methylaminoacetonitrile, N-methylaminopropionitrile, and sar- Instrumentation. The instrumentation, cells, and conditions cosine. The nitrosating agent generated by the reaction be used for DPP and spectral studies have been previously de tween ascorbic acid and nitrite ion appears to be oxyhyponitrite scribed (6, 7). The pH was measured with a Leeds & Northrup ion (N2CV2). -
"This Is the Peer Reviewed Version of the Following Article: [Drug and Alcohol Review, 2019, 38 (5), Pp
"This is the peer reviewed version of the following article: [Drug and Alcohol Review, 2019, 38 (5), pp. 465 - 472], which has been published in final form at [https://doi.org/10.1111/dar.12958] This article may be used for non‐commercial purposes in accordance with Wiley Terms and Conditions for Self‐Archiving Harmless? A hierarchical analysis of poppers use correlates among young gay and bisexual men Daniel Demant, PhDa,b* & Oscar Oviedo-Trespalacios, PhDc a Lecturer, Australian Centre for Public and Population Health Research, Faculty of Health, University of Technology Sydney, Ultimo, Australia b Visiting Fellow, School of Public Health and Social Work, Faculty of Health, Queensland University of Technology (QUT), Brisbane, Australia c Research Fellow, Centre for Accident Research and Road Safety-Queensland (CARRS-Q), Institute of Health and Biomedical Innovation (IHBI), Faculty of Health, Queensland University of Technology (QUT), Brisbane, Australia *Corresponding Author Dr Daniel Demant Lecturer in Public Health Australian Centre for Public and Population Health Research Faculty of Health University of Technology Sydney 235-253 Jones Street, Ultimo, New South Wales 2007, Australia Tel: +61 02 9514 5499 Email: [email protected] ORCiD Daniel Demant: 0000-0003-3330-2972 Oscar Oviedo-Trespalacios: 0000-0001-5916-3996 Running title: Poppers use among young gay and bisexual men Abstract Introduction: Poppers (alkyl nitrites) are recreational substances commonly used during sexual activity. The current legal status of poppers is complex and wide-ranging bans are increasingly under discussion. Research has identified disproportionate levels of poppers use in sexual minority men. While research on poppers use among sexual minority men exists, little is known about poppers use patterns and correlations with psycho-social and other factors among gay and bisexual young men. -
Does N-Nitrosomelatonin Compete with S-Nitrosothiols As a Long
nalytic A al & B y i tr o Singh et al., Biochem Anal Biochem 2016, 5:1 s c i h e m m Biochemistry & e DOI: 10.4172/2161-1009.1000262 i h s c t r o i y B ISSN: 2161-1009 Analytical Biochemistry Commentary Open Access Does N-Nitrosomelatonin Compete with S-Nitrosothiols as a Long Distance Nitric Oxide Carrier in Plants? Neha Singh, Harmeet Kaur, Sunita Yadav and Satich C Bhatla* Laboratory of Plant Physiology and Biochemistry, Department of Botany, University of Delhi, India Plants transmit a variety of signaling molecules from roots to of proteins [13]. aerial parts, and vice-versa, in response to their growth conditions Determination of GSNO in plant samples still presents a (environment, nutrients, stress factors etc.). A signaling molecule challenge due to several technical obstacles and cumbersome sample should be produced quickly, induce a defined effect within the cell preparation procedures. It can also be affected by light, metal-catalyzed and be removed or metabolized rapidly when not required. Nitric SNO decomposition, enzymatic degradation catalyzed by GSNO oxide (NO) plays significant signaling roles in plant cells since it has reductase, and a reduction in the S-NO bond caused by reductants and all the above-stated features. It is a gaseous free radical, can gain or endogenous thiols [13]. Two different approaches to detect GSNO have lose an electron, has short half-life ( ̴ 30 sec) and it can exist in three been reported in higher plants: immunohistochemical analysis using interchangeable forms, namely the radical (NO•), the nitrosonium commercial antibodies against GSNO and liquid chromatography- cation (NO+) and as nitroxyl radical (NO). -
US5489610.Pdf
|||||||| US00548961OA United States Patent 19 11 Patent Number: 5,489,610 Fung et al. 45) Date of Patent: 8 Feb. 6, 1996 54 SUSTAINED RELEASE ORGANIC NITRITE 58 Field of Search .................................... 514/506, 509, THERAPY 514/645, 740 75 Inventors: Ho-Leung Fung, Getzville; John A. 56) References Cited Bauer, Williamsville, both of N.Y. U.S. PATENT DOCUMENTS 73 Assignee: Research Foundation of the State 5,278,192 l/1994 Fung et al. .............................. 514f645 University of New York, Albany, N.Y. OTHER PUBLICATIONS * Notice: The portion of the term of this patent Derwent Abstracts 78–35053A, "Medicaments for Treating disclaimed.subsequent to Jan. 11, 2011, has been Cardiardiogenic Shock”, Fribolinis is et al. (1978). Patent Abstracts of Japan, vol. 12, No. 467, Dec. 7, 1988, 21 Appl. No.: 199,280 "Tape Preparation'. 22, PCT Filed: Jun. 30, 1993 Primary Examiner-Frederick Krass Attorney, Agent, or Firm-Kirschstein et al. 86 PCT No.: PCT/US93/06235 (57) ABSTRACT S371 Date: Mar. 1, 1994 A method of treating a patient suffering from a condition S 102(e) Date: Mar. 1, 1994 requiring vasodilator therapy, comprising long term, con 87 PCT Pub. No.: WO94/01103 tinuous adminstration of an organic nitrite to the patient in a dosage form capable of delivering a sufficient therapeutic PCT Pub. Date:Jan. 20, 1994 amount of nitrite to the bloodstream of the patient thereby providing effective vasodilator therapy for at least 24 hours Related U.S. Application Data without the development of tolerance in the patient. The a method of the invention is useful in treating conditions such 63 Continuation-in-part of Ser. -
Regulation of Protein Function by S-Nitrosation and S-Glutathionylation: Processes and Targets in Cardiovascular Pathophysiology
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio della Ricerca - Università di Pisa Biol. Chem. 2017; 398(12): 1267–1293 Review Eugenia Belcastro, Caroline Gaucher, Alessandro Corti, Pierre Leroy, Isabelle Lartaud and Alfonso Pompella* Regulation of protein function by S-nitrosation and S-glutathionylation: processes and targets in cardiovascular pathophysiology https://doi.org/10.1515/hsz-2017-0150 aims to provide an update of available knowledge in the Received April 26, 2017; accepted August 7, 2017; previously field, with a special focus on the respective (sometimes published online August 19, 2017 competing and antagonistic) roles played by protein S-nitrosations and S-thionylations in biochemical and cel- Abstract: Decades of chemical, biochemical and patho- lular processes specifically pertaining to pathogenesis of physiological research have established the relevance cardiovascular diseases. of post-translational protein modifications induced by processes related to oxidative stress, with critical reflec- Keywords: cardiovascular diseases; glutathione; mixed tions on cellular signal transduction pathways. A great disulfides; nitric oxide; RNS; ROS; S-glutathionylation; deal of the so-called ‘redox regulation’ of cell function is S-nitrosation. in fact mediated through reactions promoted by reactive oxygen and nitrogen species on more or less specific ami- noacid residues in proteins, at various levels within the cell machinery. Modifications involving cysteine residues Introduction have received most attention, due to the critical roles they The role of nitric oxide (NO) in several signaling routes play in determining the structure/function correlates in has been clearly established (Grisham et al., 1999; Pacher proteins. The peculiar reactivity of these residues results et al., 2007). -
Non-Canonical Chemical Feedback Self-Limits Nitric Oxide-Cyclic GMP Signaling in Health and Disease Vu Thao-Vi Dao1,2,9, Mahmoud H
www.nature.com/scientificreports OPEN Non-canonical chemical feedback self-limits nitric oxide-cyclic GMP signaling in health and disease Vu Thao-Vi Dao1,2,9, Mahmoud H. Elbatreek1,3,9 ✉ , Martin Deile4, Pavel I. Nedvetsky5, Andreas Güldner6, César Ibarra-Alvarado7, Axel Gödecke8 & Harald H. H. W. Schmidt1 ✉ Nitric oxide (NO)-cyclic GMP (cGMP) signaling is a vasoprotective pathway therapeutically targeted, for example, in pulmonary hypertension. Its dysregulation in disease is incompletely understood. Here we show in pulmonary artery endothelial cells that feedback inhibition by NO of the NO receptor, the cGMP forming soluble guanylate cyclase (sGC), may contribute to this. Both endogenous NO from endothelial NO synthase and exogenous NO from NO donor compounds decreased sGC protein and activity. This efect was not mediated by cGMP as the NO-independent sGC stimulator, or direct activation of cGMP- dependent protein kinase did not mimic it. Thiol-sensitive mechanisms were also not involved as the thiol-reducing agent N-acetyl-L-cysteine did not prevent this feedback. Instead, both in-vitro and in- vivo and in health and acute respiratory lung disease, chronically elevated NO led to the inactivation and degradation of sGC while leaving the heme-free isoform, apo-sGC, intact or even increasing its levels. Thus, NO regulates sGC in a bimodal manner, acutely stimulating and chronically inhibiting, as part of self-limiting direct feedback that is cGMP independent. In high NO disease conditions, this is aggravated but can be functionally recovered in a mechanism-based manner by apo-sGC activators that re-establish cGMP formation. Te nitric oxide (NO)-cGMP signaling pathway plays several essential roles in physiology, including cardio- pulmonary homeostasis1,2.